|
|
Article: GENENTECH CLINICAL TRIALS TO TEST TNKASE WITH OTHER DRUGS.(Brief Article)
- Article from:
- Biotech Business
- Article date:
- April 1, 2000
CopyrightCOPYRIGHT 2000 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genentech, Inc. (NYSE:DNA), South San Francisco, has announced plans to collaborate with other major pharmaceutical manufacturers to test the new, single-bolus thrombolytic, TNKase(TM) (Tenecteplase), in combination with various leading anti-thrombotic agents in the treatment of acute myocardial infarction (AMI), or heart attack, as part of four clinical trials involving nearly 9,000 patients. TNKase is currently under regulatory review by the U.S. Food and Drug Administration and the European Regulatory Authority for marketing approval for the treatment of AMI.
The goal of the comprehensive trial plan, commenced during the first quarter of 2000, is to assess ...